Monitoring liver transplant recipients for early detection of complications
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is testing if checking blood, urine, and tissue samples from liver transplant patients can help spot early signs of kidney problems, organ rejection, and Hepatitis C to improve their treatment and health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT01644903 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze blood, urine, and tissue samples from liver transplant recipients to identify early signs of Chronic Kidney Disease (CKD), Acute Rejection (AR), and Hepatitis C Virus (HCV). By utilizing advanced molecular techniques and biomarkers, the study seeks to improve the sensitivity and specificity of early detection compared to traditional methods. The goal is to enhance treatment outcomes and potentially reduce the need for repeat organ transplants through timely intervention.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are undergoing liver transplantation, whether from living or deceased donors.
Not a fit: Patients who are unable or unwilling to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and treatment of complications in liver transplant recipients, improving their overall health and longevity.
How similar studies have performed: Previous studies have shown promise in using molecular techniques for early detection of transplant complications, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male and female recipients of all races, ≥18 years of age. 2. Patients undergoing primary or subsequent living or deceased donor liver transplantation. 3. Subject and/or guardian must be able to provide informed consent. 4. Subject and/or guardian must be able to comply with the study protocol. Exclusion Criteria: 1\. Inability or unwillingness of a participant and/or guardian to provide informed consent.
Where this trial is running
Chicago, Illinois
- Northwestern Memorial Hospital — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Josh Levitsky, MD — Northwestern University
- Study coordinator: Misael Villegas, BA
- Email: misael.villegas@northwestern.edu
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.